CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $2.7B, above the global median of $548.88M
- PositionGross margin is 6.2%, lower than 95% of its Pharmaceutical Retailers peers (median 25.6%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.94%Below 5Y avg (2.08%)
Annual Rate
CNY 0.12Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Aug 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.56BCNY530.83M · vs all stocks (USD)
Trailing P/E
39.45xvs Pharmaceutical Retailers peers
Revenue (TTM)
18.10BCNY2.70B · vs all stocks (USD)
Profit Margin
0.50%vs Pharmaceutical Retailers peers
Beta
0.3550xvs all stocks
52-Week Change
-10.82%vs all stocks
Market Capitalization
3.56BCNY530.83M · vs all stocks (USD)
Enterprise Value
4.04BCNY603.10M · vs all stocks (USD)
Trailing P/E
39.45xvs Pharmaceutical Retailers peers
Forward P/E
7.37xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.1971xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
0.8038xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.2230xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
15.04xvs Pharmaceutical Retailers peers
Gross Margin
6.16%vs Pharmaceutical Retailers peers
Profit Margin
0.50%vs Pharmaceutical Retailers peers
Operating Margin
2.36%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
1.41%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
0.88%vs Pharmaceutical Retailers peers
Revenue (TTM)
18.10BCNY2.70B · vs all stocks (USD)
Revenue per Share (TTM)
61.84CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-14.20%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
1.06BCNY157.48M · vs all stocks (USD)
EBITDA (TTM)
489.71MCNY73.05M · vs all stocks (USD)
Net Income (TTM)
90.88MCNY13.55M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-20.40%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
1.38BCNY205.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.60BCNY239.28M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1150CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.94%vs all stocks
5-Year Average Dividend Yield
2.08%vs all stocks
Payout Ratio
0.00%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
1.52BCNYFY2025 · Dec 31, 2025Revenue
19.53BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
18.28BCNYFY2025 · Dec 31, 2025Gross Profit
1.25BCNYFY2025 · Dec 31, 2025Operating Income
717.07MCNY106.96M · vs all stocks (USD)
Pre-tax Income
278.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
176.38MCNYFY2025 · Dec 31, 2025Net Income
101.71MCNYFY2025 · Dec 31, 2025EBIT
360.69MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
812.59MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
81.17MCNYFY2025 · Dec 31, 2025Other Operating Expenses
34.14MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
12.00MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
82.60MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
293.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
293.10MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
101.71MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
9.67MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.34BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.32BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.45BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
101.71MCNYFY2025 · Dec 31, 2025Other Non-cash Items
100.23MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
914.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
225.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-20.85MCNYFY2025 · Dec 31, 2025Net Acquisitions
19.58MCNYFY2025 · Dec 31, 2025Sale of Investments
525.87KCNYFY2025 · Dec 31, 2025Other Investing Activity
-5.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.74MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.19BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.04BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-108.87MCNYFY2025 · Dec 31, 2025Other Financing Charges
24.57MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-926.40MCNYFY2025 · Dec 31, 2025Shares Outstanding
291.71MSharesUpdated Sep 19, 2026Float Shares
186.12MSharesUpdated Sep 19, 2026% Held by Insiders
43.17%vs all stocks
% Held by Institutions
0.48%vs all stocks
Total Cash (MRQ)
2.62BCNY391.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.99CNYUpdated Sep 19, 2026Total Debt (MRQ)
1.61BCNY239.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2695xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.93xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
15.22CNYUpdated Sep 19, 2026Total Assets
12.75BCNY1.90B · vs all stocks (USD)
Total Current Assets
11.83BCNYFY2025 · Dec 31, 2025Total Liabilities
6.87BCNYFY2025 · Dec 31, 2025Total Non-current Assets
913.61MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
105.76MCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.77BCNYFY2025 · Dec 31, 2025Cash
2.45BCNYFY2025 · Dec 31, 2025Cash Equivalents
103.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.56BCNYFY2025 · Dec 31, 2025Other Short-term Investments
5.14MCNYFY2025 · Dec 31, 2025Accounts Receivable
5.89BCNYFY2025 · Dec 31, 2025Inventory
2.47BCNYFY2025 · Dec 31, 2025Accounts Payable
4.22BCNYFY2025 · Dec 31, 2025Short-term Debt
1.74BCNYFY2025 · Dec 31, 2025Other Current Liabilities
143.85MCNYFY2025 · Dec 31, 2025Long-term Debt
104.37MCNYFY2025 · Dec 31, 2025Common Stock (Book)
291.71MCNYFY2025 · Dec 31, 2025Retained Earnings
2.54BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.88BCNY876.44M · vs all stocks (USD)
52-Week Low
10.57CNYUpdated Sep 19, 202652-Week High
19.69CNYUpdated Sep 19, 202652-Week Change
-10.82%vs all stocks
Beta
0.3550xvs all stocks
50-Day MA
11.96CNYUpdated Sep 19, 2026200-Day MA
13.94CNYUpdated Sep 19, 2026Avg 10-Day Volume
2.33MSharesUpdated Sep 19, 2026Avg 30-Day Volume
3.15MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.3100CNYUpdated Sep 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 6.2%, lower than 95% of its Pharmaceutical Retailers peers (median 25.6%)Significant
Gross margin: 0.06Industry median: 0.26Industry P5: 0.07Peers compared: 21.00
Current ratio is 1.93×, higher than 95% of its Pharmaceutical Retailers peers (median 1.36×)Significant
Current ratio: 1.93Industry median: 1.36Industry P95: 1.83Peers compared: 21.00
Financial Health
Altman Z-Score 2.69: safe zoneNotable
Altman Z-Score: 2.69
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $2.7B, above the global median of $548.88MNotable
Revenue (USD): 2,700,387,523.215Global Median: 548,883,780.48
Levered free cash flow is $239.28M, above the global median of $18.73MNotable
Levered free cash flow (USD): 239,275,512.791Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Erajaya Swasembada Tbk.
Tier 1FlowUnit ReplicationInterfaceRisk
Jm Holdings Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
SMCP S.A.
Tier 1FlowUnit ReplicationRiskInterface
Daikokutenbussan Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Tokmanni Group Oyj
Tier 1FlowUnit ReplicationProductionInterface
Haoyun Technologies Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Carriage Services Inc.
Tier 1FlowUnit ReplicationRuleProduction
Empreendimentos Pague Menos S.A.
Tier 1FlowUnit ReplicationProductionInterface
Delek Automotive Systems Ltd.
Tier 1FlowUnit ReplicationInterfaceRisk
Pharmacy Chain 36.6 PJSC
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
Stantec Inc.
2 interpretationsClose Below 40W SMA With ProfitabilityFCF Ratios Elevated
Shenzhen Liantronics Co., Ltd.
2 interpretationsClose Below 40W SMA With ProfitabilityFCF Ratios Elevated
Ford Otomotiv Sanayi A.Ş.
2 interpretationsClose Below 40W SMA With ProfitabilityFCF Ratios Elevated